Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain

Synapse ◽  
1990 ◽  
Vol 6 (2) ◽  
pp. 146-153 ◽  
Author(s):  
Steven J. O'Dell ◽  
Gerald J. Lahoste ◽  
Clifford B. Widmark ◽  
Raymond M. Shapiro ◽  
Steven G. Potkin ◽  
...  
Keyword(s):  
Rat Brain ◽  
Serotonin Receptors ◽  
Chronic Treatment ◽  
Dopamine And Serotonin Receptors

Effect of carbidine on dopamine and serotonin receptors of the CNS

1985 ◽  
Vol 99 (6) ◽  
pp. 754-756 ◽  
Author(s):  
A. M. Zharkovskii ◽  
N. E. Klassen ◽  
T. A. Zharkovskaya
Keyword(s):  
Serotonin Receptors ◽  
Dopamine And Serotonin Receptors

[3H]Metergoline: A New Ligand of Serotonin Receptors in the Rat Brain

1981 ◽  
Vol 36 (2) ◽  
pp. 613-626 ◽  
Author(s):  
M. Hamon ◽  
M. Mallat ◽  
A. Herbet ◽  
D. L. Nelson ◽  
M. Audinot ◽  
...  
Keyword(s):  
Rat Brain ◽  
Serotonin Receptors

scholarly journals Alteration of nicotinic receptors in rat brain following chronic treatment with nicotine or cigaratte smoke.

1994 ◽  
Vol 64 ◽  
pp. 184
Author(s):  
Shinya Tsuchida ◽  
Masahiro Hiraoka ◽  
Masakatsu Sudo ◽  
Manabu Takita ◽  
Shigeru Kigoshi ◽  
...  
Keyword(s):  
Rat Brain ◽  
Nicotinic Receptors ◽  
Chronic Treatment

Chronic treatment with prolixin causes oxidative stress in rat brain

1990 ◽  
Vol 28 (8) ◽  
pp. 738-740 ◽  
Author(s):  
Jean Lud Cadet ◽  
Arthur S. Perumal
Keyword(s):  
Oxidative Stress ◽  
Rat Brain ◽  
Chronic Treatment

scholarly journals Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: A New Class of Atypical Antipsychotics

2020 ◽  
Vol 13 (11) ◽  
pp. 388
Author(s):  
Irene Fasciani ◽  
Francesco Petragnano ◽  
Gabriella Aloisi ◽  
Francesco Marampon ◽  
Marco Carli ◽  
...  
Keyword(s):  
Serotonin Receptors ◽  
Atypical Antipsychotics ◽  
Binding Pocket ◽  
Mental Illnesses ◽  
Psychiatric Disease ◽  
Allosteric Modulators ◽  
New Class ◽  
Dopamine And Serotonin Receptors ◽  
New Generation ◽  
The 19Th Century

Schizophrenia was first described by Emil Krapelin in the 19th century as one of the major mental illnesses causing disability worldwide. Since the introduction of chlorpromazine in 1952, strategies aimed at modifying the activity of dopamine receptors have played a major role for the treatment of schizophrenia. The introduction of atypical antipsychotics with clozapine broadened the range of potential targets for the treatment of this psychiatric disease, as they also modify the activity of the serotoninergic receptors. Interestingly, all marketed drugs for schizophrenia bind to the orthosteric binding pocket of the receptor as competitive antagonists or partial agonists. In recent years, a strong effort to develop allosteric modulators as potential therapeutic agents for schizophrenia was made, mainly for the several advantages in their use. In particular, the allosteric binding sites are topographically distinct from the orthosteric pockets, and thus drugs targeting these sites have a higher degree of receptor subunit specificity. Moreover, “pure” allosteric modulators maintain the temporal and spatial fidelity of native orthosteric ligand. Furthermore, allosteric modulators have a “ceiling effect”, and their modulatory effect is saturated above certain concentrations. In this review, we summarize the progresses made in the identification of allosteric drugs for dopamine and serotonin receptors, which could lead to a new generation of atypical antipsychotics with a better profile, especially in terms of reduced side effects.

Sign in / Sign up

Export Citation Format

Share Document